Inomax Generic Name & Formulations
Nitric oxide 800ppm; gas for inh.
Cylinders (Size D)—353L; (Size 88)—1963L
To improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
Inomax Dosage and Administration
20ppm for up to 14 days or until underlying oxygen desaturation resolved. >20ppm: not recommended.
Neonates dependent on right-to-left shunting of blood.
Inomax Boxed Warnings
Avoid abrupt discontinuation. Rebound pulmonary hypertension syndrome; if occurs, restart treatment immediately. Measure methemoglobin within 4–8hrs after initiation and periodically during therapy. Monitor for hypoxemia. Airway injury due to nitrogen dioxide (NO2). Monitor for PaO2 and inspired NO2 during administration. Pre-existing left ventricular dysfunction; worsening heart failure may occur (eg, pulmonary edema, increased pulmonary capillary wedge pressure, systemic hypotension, others); discontinue and treat if develops.
Increased risk of methemoglobinemia with concomitant nitric oxide donor agents (eg, prilocaine, sodium nitroprusside, nitroglycerine).
Inomax Adverse Reactions
Hypotension; hypoxemia, worsening heart failure.
Inomax Clinical Trials
Inomax Patient Counseling